Drugs / YTTRIUM Y 90 EPRATUZUMAB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01147393 | Oct 2010 → Aug 2013 | follicular lymphoma | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01101581 | May 2010 → Dec 2016 | diffuse large B-cell lymphoma | Gilead Sciences | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00421395 | Aug 2002 → Oct 2007 | B-cell non-Hodgkin lymphoma | Gilead Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02844530 | ? → Jan 2017 | B-cell acute lymphoblastic leukemia | Nantes University Hospital | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YTTRIUM Y 90 EPRATUZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108817 ↗ |
| Known as | 90Y-epratuzumab tetraxetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01147393 ↗ |
| Known as | 90Y-hLL2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00421395 ↗ |
| Known as | Epratuzumab (y 90) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108817 ↗ |
| Known as | S9S0Y-HLL2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108817 ↗ |
| Modality | Monoclonal antibody | “intact monoclonal antibody IgG” NCT00421395 ↗ |
| Route | Intravenous | “90Y-Epratuzumab tetraxetan will be administered intravenously.” NCT01101581 ↗ |
| Target | CD22 | “90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy” NCT01147393 ↗ |